PTAB Invalidates Patent For Biogen's Cancer Drug Rituxan
The Patent Trial and Appeal Board has invalidated the entirety of a Biogen Inc. patent for its cancer treatment Rituxan, following a challenge by South Korea's Celltrion Inc....To view the full article, register now.
Already a subscriber? Click here to view full article